Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
CYP1A2 overexpression
Cancer:
Hepatocellular Cancer
Drug:
sorafenib
(
Multi-tyrosine kinase inhibitor
,
pan-RAF inhibitor
)
Direction:
Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
AACR-II 2020
Title:
/ 16 - Omeprazole and sorafenib in combination reverses sorafenib-resistance by inhibiting NF-?B signaling in hepatocellular carcinoma
Published date:
05/15/2020
Excerpt:
MTT assay showed that the overexpression of CYP1A2 enhanced the sensitivity of SR cells against sorafenib and vice versa.
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.